Vertex Pharmaceuticals Inc (VRTX) KPIs and segments
Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Vertex Pharmaceuticals · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Vertex Pharmaceuticals: 45 chỉ số vận hành, trong đó có Estimated Cystic Fibrosis patient population in U.S., JOURNAVX và CASGEVY, lấy từ 218 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Products($M) | 3,334 | 2,987 | 3,190 | 3,076 | 2,944 | 2,760 | 2,912 | 2,772 | 2,646 | 2,691 | |||
TRIKAFTA/KAFTRIO($M) | 2,497 | 2,355 | 2,573 | 2,654 | 2,551 | 2,536 | 2,721 | 2,585 | 2,449 | 2,484 | 2,333 | 2,274 | |
ALYFTREK($M) | 574 | 424 | 380 | 247 | 157 | 53.9 | 0 | 0 | 0 | 0 | |||
Other CF product revenues($M) | 137 | 136 | 237 | 176 | 194 | 155 | 191 | 187 | 196 | 207 | 184 | 209 | |
CASGEVY($M) | 76.4 | 42.9 | 54.3 | 16.9 | 30.4 | 14.2 | 8 | 2 | 0 | ||||
JOURNAVX($M) | 49.6 | 29 | 26.7 | 19.6 | 12 | 1.30 | 0 | 0 | 0 | ||||
Other revenues($M) | 0 | 0 | 0 | 0 | 20.7 | 10 | 0 | 0 | 0 | 0 | |||
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)5 | |||||||||||||
United States($M) | 2,056 | 1,776 | 1,976 | 1,848 | 1,664 | 1,837 | 1,714 | 1,614 | 1,520 | 1,575 | 1,554 | ||
Europe($M) | 978 | 950 | 837 | 911 | 827 | 832 | 848 | 807 | 967 | 735 | 767 | ||
Other($M) | 300 | 261 | 263 | 206 | 280 | 211 | 225 | 203 | 163 | ||||
JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx)1 | 535,000.00 | 350,000.00 | 280,000.00 | 170,000.00 | 90,000.00 | 10,000.00 | |||||||
JOURNAVX — State Medicaid plans with fee-for-service coverage (states) | 21.00 | 19.00 | 16.00 | 10.00 | |||||||||
CASGEVY (exagamglogene autotemcel, CRISPR/Cas9 gene-edited therapy) — Patient infusions in period (patients)2 | 30.00 | 10.00 | 16.00 | 8.00 | |||||||||
CASGEVY — Patients with first cell collection in period (patients) | 37.00 | 50.00 | 35.00 | 25.00 | |||||||||
CASGEVY — Cumulative patients with cell collections since launch (patients) | 165.00 | 115.00 | 90.00 | 50.00 | 40.00 | 20.00 | |||||||
Total consolidated revenues ($M)($M)1 | 3,334 | 2,987 | 3,190 | 3,076 | 2,965 | 2,770 | 2,912 | 2,772 | 2,646 | 2,691 | 2,518 | 2,484 | |
Foreign currency cash flow hedge gain (loss) reclassified to net product revenues ($M)($M) | -10.2 | -25.5 | -37.1 | -39 | -21.3 | 24.1 | 24.5 | -3.10 | 10.9 | 3.40 | -2.80 | 2.80 | |
Net product revenues by geography — United States (U.S.) ($M)($M)1 | 2,056 | 1,776 | 2,091 | 1,976 | 1,848 | 1,664 | 1,837 | 1,714 | 1,614 | 1,520 | 1,575 | 1,554 | |
Outside the United States (Ex-U.S. total net product revenues, $M)($M)2 | 1,278 | 1,211 | 1,129 | 1,100 | 1,117 | 1,107 | 1,075 | 1,058 | 1,031 | 1,171 | 943 | 929 | |
Europe — Net product revenues ($M)($M) | 978 | 950 | 886 | 837 | 911 | 827 | 832 | 848 | 807 | 967 | 735 | 767 | |
Other international markets (Ex-U.S. & Ex-Europe) — Net product revenues ($M)($M) | 300 | 261 | 244 | 263 | 206 | 280 | 243 | 211 | 225 | 203 | 208 | 163 | |
Total contract liabilities (deferred product & collaborative revenue, $M)($M)1 | 157 | 219 | 172 | 182 | 147 | 228 | 207 | 220 | 128 | 276 | 170 | 157 | |
Contract liabilities — Annual reimbursement cap contracts for CF medicines in ex-U.S. government markets ($M)($M) | 157 | 219 | 172 | 182 | 147 | 228 | 207 | 220 | 128 | 276 | 170 | 157 | |
Total accrued expenses ($M)($M) | 3,179 | 2,984 | 2,971 | 3,614 | 3,271 | 2,952 | 2,789 | 3,220 | 2,940 | 2,796 | 2,655 | 2,907 | |
Level 3 contingent consideration liabilities — Total fair value ($M)($M)5 | 79.6 | 79.2 | 79 | 78.1 | 80 | 79.1 | 76.9 | 78.1 | 77.8 | 77.3 | 77.4 | 128 | |
Contingent consideration liabilities — Noncurrent ($M)($M) | 79.6 | 79.2 | 79 | 78.1 | 80 | 79.1 | 76.9 | 78.1 | 77.8 | 77.3 | 77.4 | 113 | |
Contingent consideration liabilities — Current (historical, $M)($M) | 0 | 15 | |||||||||||
Contingent consideration — Remaining potential development & regulatory milestones (historical, $M)($M) | 678 | 678 | |||||||||||
Contingent consideration valuation — Discount rate range minimum (%)(%) | 460.0% | 440.0% | 410.0% | 420.0% | 440.0% | 450.0% | 490.0% | 430.0% | 510.0% | 510.0% | 470.0% | 550.0% | |
Contingent consideration valuation — Discount rate range maximum (%)(%) | 470.0% | 460.0% | 450.0% | 450.0% | 460.0% | 460.0% | 510.0% | 440.0% | 560.0% | 530.0% | 490.0% | 650.0% | |
Total Research and Development (R&D) expenses ($M)($M)2 | 994 | 962 | 974 | 978 | 978 | 980 | 999 | 876 | 967 | 789 | 825 | 810 | |
Research expenses (discovery & early preclinical) — Total ($M)($M)4 | 207 | 205 | 203 | 210 | 209 | 206 | 207 | 194 | 207 | 196 | 194 | 174 | |
Research — Salary and employee benefits ($M)($M) | 51.3 | 55.2 | 48.1 | 49.6 | 53.1 | 53.1 | 47.5 | 48.3 | 61.9 | 53 | 46.6 | 46.3 | |
Research — Stock-based compensation expense ($M)($M) | 21.2 | 21.2 | 22 | 28 | 22.5 | 22.3 | 24.2 | 29.4 | 28.6 | 29.9 | 33.2 | 20.5 | |
Research — Outsourced services and other direct costs ($M)($M) | 71.2 | 66.6 | 69.9 | 72.2 | 71 | 73.1 | 75.9 | 64.1 | 67 | 64.4 | 61 | 61.8 | |
Research — Infrastructure and facilities costs ($M)($M) | 63.6 | 62 | 62.5 | 60.2 | 62.7 | 57.6 | 59.7 | 52 | 49.8 | 48.8 | 53.4 | 45.3 | |
Development expenses (clinical trials, regulatory & CMC) — Total ($M)($M)4 | 787 | 757 | 771 | 768 | 769 | 774 | 791 | 682 | 759 | 593 | 630 | 636 | |
Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M)($M) | 368 | 326 | 377 | 365 | 373 | 380 | 416 | 319 | 267 | 236 | 282 | 333 | |
Development — Salary and employee benefits ($M)($M) | 194 | 213 | 179 | 182 | 187 | 196 | 177 | 173 | 167 | 170 | 152 | 152 | |
Development — Stock-based compensation expense ($M)($M) | 83.2 | 80.5 | 77.7 | 88 | 77.1 | 77.8 | 74.1 | 81.6 | 68.5 | 89.5 | 89.8 | 60.6 | |
Development — Infrastructure and facilities costs ($M)($M) | 142 | 137 | 138 | 133 | 132 | 120 | 124 | 108 | 105 | 97.3 | 107 | 90.6 | |
Acquired in-process research and development (AIPR&D) expenses ($M)($M)1 | 21.4 | 0.50 | 56.5 | 54.5 | 2.20 | 19.8 | 87.5 | 15 | 4,449 | 76.8 | 17.8 | 51.7 | |
Intangible asset (IPR&D) impairment charges ($M)($M) | 0 | 0 | 0 | 0 | 0 | 379 | 0 | 0 | 0 | 0 | |||
Cost of sales — Total ($M)($M)3 | 489 | 393 | 466 | 415 | 408 | 363 | 423 | 393 | 372 | 343 | 368 | 319 | |
Cost of sales — Product manufacturing, logistics & write-downs (ex-royalties, $M)($M) | 218 | 160 | 191 | 140 | 141 | 131 | 152 | 132 | 124 | 109 | |||
Cost of sales — Royalty expense (CFF & third-party royalties, $M)($M) | 271 | 233 | 275 | 275 | 267 | 232 | 271 | 261 | 248 | 234 | |||
Cost of sales as % of net product revenues (%)(%) | 14.7% | 13.2% | 13.5% | 13.8% | 13.2% | 14.2% | 13.0% | 13.0% | 13.0% | ||||
Selling, general and administrative (SG&A) expenses — Total ($M)($M)3 | 582 | 494 | 487 | 445 | 425 | 396 | 378 | 372 | 372 | 343 | 369 | 264 | |
SG&A — Selling and marketing expenses ($M)($M) | 388 | 314 | 319 | 278 | 265 | 241 | 234 | 217 | 196 | 192 | |||
SG&A — General and administrative expenses ($M)($M) | 194 | 180 | 168 | 167 | 160 | 155 | 144 | 155 | 176 | 151 | |||
Segment other items (other operating & non-operating segment items, $M)($M) | -23.9 | 0.20 | -2.30 | 11.2 | -12.3 | 19.8 | 16.5 | 24.7 | 33.5 | 41.5 | |||
CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M)($M)4 | 14.4 | 16.1 | 16.8 | 14.3 | 15.1 | 16 | -3.40 | 11.7 | 11.6 | 11.7 | 13.6 | 12.5 | |
CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M)($M) | 21.8 | 23.1 | 37.2 | 43.3 | 30.1 | 36.2 | 26 | 15.8 | 15.9 | 15.8 | |||
CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M)($M) | 10.9 | 7 | |||||||||||
CRISPR Collaboration — Vertex share of CASGEVY net profits / losses (%)(%) | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | ||
CRISPR Collaboration — Vertex share of program development costs (%)(%) | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | 4,000.0% | ||
Non-GAAP net income ($M)($M)6 | 1,207 | 1,147 | 1,287 | 1,236 | 1,169 | 1,054 | 1,036 | 1,143 | -3,311 | 1,242 | 1,097 | 1,064 | |
Non-GAAP diluted earnings per share ($/sh)($) | 4.73 | 4.47 | 5.03 | 4.80 | 4.52 | 4.06 | 3.98 | 4.38 | -12.83 | 4.76 | 4.20 | 4.08 | |
Non-GAAP operating income ($M)($M) | 1,423 | 1,310 | 1,370 | 1,385 | 1,325 | 1,183 | 1,198 | 1,307 | -3,146 | 1,336 | 1,151 | 1,173 | |
Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M)($M)2 | 1,430 | 1,292 | 1,362 | 1,285 | 1,240 | 1,232 | 1,297 | 1,079 | 5,427 | 1,019 | 984 | 942 | |
Non-GAAP research and development (R&D) expenses ($M)($M) | 889 | 859 | 873 | 861 | 878 | 879 | 900 | 764 | 697 | 670 | 699 | 726 | |
Non-GAAP selling, general and administrative (SG&A) expenses ($M)($M) | 520 | 432 | 432 | 369 | 359 | 333 | 310 | 300 | 280 | 272 | 286 | 216 | |
Non-GAAP cost of sales ($M)($M) | 480 | 385 | 458 | 407 | 400 | 355 | 416 | 386 | 365 | 336 | 364 | 317 | |
Total pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M)($M) | 139 | 174 | 157 | 201 | 169 | 568 | 180 | 202 | 381 | 224 | 163 | 141 | |
Non-GAAP provision for income taxes ($M)($M)2 | 324 | 280 | 201 | 264 | 282 | 244 | 280 | 283 | 301 | 261 | 214 | 257 | |
Non-GAAP effective tax rate (%)(%) | 21.1% | 19.6% | 13.5% | 17.6% | 19.4% | 18.8% | 21.3% | 19.8% | -10.0% | 17.4% | 16.3% | 19.4% | |
GAAP effective tax rate (%)(%) | 21.0% | 17.7% | 10.5% | 16.6% | 19.5% | 11.5% | 19.7% | 14.6% | -6.0% | 14.0% | 15.6% | 12.2% | |
Total stock-based compensation (SBC) expense recognized in income statement ($M)($M)7 | 170 | 166 | 158 | 195 | 167 | 166 | 168 | 185 | 154 | 192 | 209 | 131 | |
SBC expense — Research and development ($M)($M) | 104 | 102 | 99.7 | 116 | 99.6 | 100 | 98.3 | 111 | 97.1 | 119 | 123 | 81.1 | |
SBC expense — Selling, general and administrative ($M)($M) | 62 | 61.5 | 54.7 | 76.1 | 65.2 | 63.4 | 67.5 | 71.7 | 55.3 | 70.7 | 83.5 | 48.1 | |
SBC expense — Cost of sales ($M)($M) | 3.80 | 3.20 | 3.20 | 2.80 | 2.50 | 2.60 | 2 | 1.90 | 1.80 | 1.80 | 2.10 | 1.70 | |
SBC capitalized into inventory ($M)($M) | 3.70 | 3.50 | 3.20 | 4.40 | 3.90 | 2.90 | 3.10 | 3.60 | 2.80 | 1.10 | 0.50 | 0.80 | |
Total gross stock-based compensation cost incurred (expensed + capitalized, $M)($M) | 170 | 166 | 158 | 195 | 167 | 166 | 168 | 185 | 154 | 192 | 209 | 131 | |
Income tax benefit (provision) recognized for stock-based compensation ($M)($M) | 35.3 | 35.3 | -30.6 | 47.5 | 36.5 | 75.2 | 27.3 | 64.6 | 80.7 | 79 | 58.5 | 37.1 | |
Stock-based compensation expense, net of tax ($M)($M) | 135 | 131 | 188 | 147 | 131 | 90.9 | 141 | 120 | 73.5 | 113 | 150 | 93.8 | |
SBC expense by award type — Restricted stock units (RSUs) & performance stock units (PSUs) ($M)($M)2 | 166 | 167 | 155 | 191 | 163 | 163 | 166 | 185 | 151 | 187 | 205 | 129 | |
SBC expense by award type — Stock options ($M)($M) | 2.20 | 0 | 0 | 1.20 | 0 | 0 | 1.80 | 0 | 0 | 0.20 | |||
SBC expense by award type — Employee stock purchase plan (ESPP) ($M)($M) | 5.80 | 3.40 | 5.80 | 8.50 | 7.10 | 5.60 | 4.50 | 3.40 | 4.50 | 5.80 | 4 | 2.40 | |
Total inventories, net ($M)($M)3 | 1,765 | 1,767 | 1,687 | 1,627 | 1,499 | 1,360 | 1,205 | 1,080 | 915 | 813 | 739 | 689 | |
Inventories — Raw materials ($M)($M) | 233 | 267 | 260 | 279 | 221 | 251 | 252 | 141 | 112 | 95.7 | 78.7 | 77.5 | |
Inventories — Work in process ($M)($M) | 1,254 | 1,243 | 1,197 | 1,096 | 1,064 | 901 | 769 | 750 | 658 | 602 | 525 | 498 | |
Inventories — Finished goods ($M)($M) | 278 | 256 | 230 | 252 | 214 | 208 | 185 | 189 | 145 | 116 | 135 | 113 | |
Property and equipment, net ($M)($M) | 1,665 | 1,608 | 1,520 | 1,425 | 1,335 | 1,296 | 1,228 | 1,118 | 1,201 | 1,173 | 1,159 | 1,124 | |
Intangible assets, net ($M)($M)4 | 413 | 419 | 424 | 430 | 436 | 441 | 826 | 832 | 838 | 835 | 840 | 604 | |
Indefinite-lived in-process research and development (IPR&D) intangible assets ($M)($M) | 225 | 225 | 225 | 225 | 225 | 225 | 604 | 604 | |||||
Finite-lived intangible assets — Commercialized / marketing-related, net ($M)($M)2 | 186 | 191 | 196 | 201 | 206 | 211 | 216 | 236 | |||||
Finite-lived marketing-related intangible assets — Gross carrying amount ($M)($M) | 238 | 238 | 238 | 238 | 238 | 238 | 238 | 238 | |||||
Finite-lived marketing-related intangible assets — Accumulated amortization ($M)($M) | 52.2 | 47.1 | 42.1 | 37 | 32 | 26.9 | 21.9 | 1.70 | |||||
Finite-lived intangible assets — Employment contracts, net ($M)($M) | 2.40 | 3 | 3.70 | 4.20 | 4.90 | 5.50 | 6.20 | 0 | |||||
Goodwill carrying value ($M)($M) | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,100 | 1,088 | 1,088 | 1,088 | 1,100 | 1,088 | |
Operating lease right-of-use (ROU) assets ($M)($M)1 | 1,663 | 1,685 | 1,563 | 1,592 | 1,314 | 1,339 | 1,357 | 1,396 | 570 | 313 | 294 | 311 | |
Operating lease liabilities — Total ($M)1 | |||||||||||||
Operating lease liabilities — Noncurrent ($M)($M) | 1,978 | 1,987 | 1,847 | 1,835 | 1,527 | 1,538 | 1,544 | 1,589 | 587 | 360 | 349 | 354 | |
Share repurchases — Cash paid for repurchases of common stock ($M)($M)4 | 470 | 337 | 128 | 1,071 | 392 | 426 | 418 | 308 | 320 | 131 | 150 | 117 | |
Share repurchases — Aggregate repurchase value under repurchase programs ($M)($M) | 458 | 345 | 93.3 | 1,093 | 397 | 417 | 436 | 308 | 316 | 140 | 144 | 123 | |
Share repurchases — Shares repurchased under repurchase programs (M shares)(M) | 1.10 | 0.70 | 0.30 | 2.70 | 0.90 | 0.90 | 1 | 0.60 | 0.80 | 0.30 | 0.40 | 0.40 | |
Item 2(c) / Item 5 Share Repurchases — Total shares purchased in quarter (thousands)3 | 1,033.70 | 741.10 | 256.80 | 2,728.20 | 868.70 | 932.50 | 961.10 | 640.00 | 736.00 | 335.80 | 398.00 | 352.60 | |
Item 2(c) / Item 5 — Shares purchased under publicly announced programs in quarter (thousands) | 1,033.70 | 741.10 | 256.80 | 2,728.20 | 868.70 | 932.50 | 961.10 | 640.00 | 736.00 | 335.80 | 398.00 | 352.60 | |
Item 2(c) / Item 5 — Quarterly volume-weighted average price paid per share ($/sh)($) | 440 | 465 | 409 | 397 | 454 | 447 | 445 | 481 | 429 | 418 | 361 | 349 | |
Item 2(c) / Item 5 — Remaining share repurchase authorization at quarter-end ($M)($M) | 2,582 | 3,037 | 3,382 | 3,487 | 4,570 | 964 | 1,381 | 1,809 | 2,116 | 2,432 | 2,572 | 2,716 | |
Employee tax withholding — Cash paid for shares withheld on equity vesting ($M)($M)1 | 4.30 | 229 | 2.50 | 91 | 5.90 | 271 | 7.30 | 83.7 | 80.5 | 234 | 3.20 | 53.2 | |
Employee tax withholding — Shares withheld on equity vesting (M shares)(M) | 0 | 0.50 | -0.10 | 0.20 | 0 | 0.60 | 0 | 0.20 | 0.10 | 0.60 | 0 | 0.10 | |
Income before provision for income taxes — Total ($M)($M) | 1,392 | 1,253 | 1,331 | 1,299 | 1,283 | 730 | 1,137 | 1,224 | -3,391 | 1,279 | 1,148 | 1,179 | |
Provision for (benefit from) income taxes — Total ($M)($M) | 292 | 222 | 140 | 216 | 250 | 84.1 | 224 | 179 | 202 | 180 | 179 | 144 | |
Unrecognized tax benefits (UTB) — Gross ending balance ($M)1 | |||||||||||||
UTB — Portion that would impact effective tax rate if recognized ($M)($M) | 439 | 420 | 437 | 422 | 412 | 357 | 341 | 345 | 309 | 302 | 289 | 245 | |
Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M)($M)11 | 22.5 | 22.9 | 19.2 | ||||||||||
Alpine Immune Sciences — Collaboration revenue ($M)($M) | 7.03 | 30.9 | 10.0 | ||||||||||
Alpine Immune Sciences — General and administrative expense ($M)($M) | 7.27 | 6.37 | 5.44 | ||||||||||
Alpine Immune Sciences — Total operating expenses ($M)($M) | 29.7 | 29.3 | 24.6 | ||||||||||
Alpine Immune Sciences — Operating income (loss) ($M)($M) | -22.7 | 1.54 | -14.6 | ||||||||||
Alpine Immune Sciences — Net income (loss) ($M)($M) | -17.9 | 5.97 | -11.7 | ||||||||||
Alpine Immune Sciences — Stock-based compensation expense ($M)($M) | 3.99 | 2.81 | 2.65 | ||||||||||
Alpine Immune Sciences — Cash and cash equivalents ($M)($M) | 33.0 | 43.9 | 19.0 | ||||||||||
Alpine Immune Sciences — Marketable securities ($M)($M) | 273 | 283 | 174 | ||||||||||
Alpine Immune Sciences — Total assets ($M)($M) | 374 | 380 | 241 | ||||||||||
Alpine Immune Sciences — Total liabilities ($M)($M) | 40.9 | 51.9 | 78.9 | ||||||||||
Alpine Immune Sciences — Stockholders' equity ($M)($M) | 333 | 328 | 162 | ||||||||||
Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M)($M)9 | 99.9 | 100 | 85.1 | 90.5 | 80.3 | 76.2 | 66.6 | 61.9 | 58.3 | 53.3 | 45.6 | 43.8 | |
Crinetics Pharmaceuticals — Total revenues ($M)($M) | 25.1 | 10.7 | 6.17 | 0.14 | 1.03 | 0.36 | 0 | 0 | 0.40 | 0.64 | -0.01 | 0.35 | |
Crinetics Pharmaceuticals — Operating loss ($M)($M) | -132 | -140 | -134 | -143 | -129 | -111 | -94.7 | -87.8 | -82.8 | -73.5 | -62.7 | -59.0 | |
Crinetics Pharmaceuticals — Net loss ($M)($M) | -121 | -128 | -123 | -130 | -116 | -96.8 | -80.6 | -76.8 | -74.1 | -66.9 | -60.1 | -57.5 | |
Crinetics Pharmaceuticals — Stock-based compensation expense ($M)($M) | 24.9 | 29.7 | 21.7 | 22.7 | 26.1 | 20.5 | 18.9 | 18.2 | 18.9 | 13.5 | 11.6 | 11.1 | |
Crinetics Pharmaceuticals — Cash and cash equivalents ($M)($M) | 55.5 | 114 | 102 | 111 | 53.7 | 94.6 | 265 | 317 | 302 | 396 | 54.9 | 143 | |
Crinetics Pharmaceuticals — Investment securities ($M)($M) | 1,150 | 1,177 | 926 | 981 | 1,143 | 1,180 | 1,090 | 545 | 561 | 505 | 504 | 412 | |
Crinetics Pharmaceuticals — Total assets ($M)($M) | 1,322 | 1,401 | 1,126 | 1,196 | 1,290 | 1,361 | 1,435 | 937 | 936 | 978 | 635 | 642 | |
Crinetics Pharmaceuticals — Total liabilities ($M)($M) | 130 | 121 | 134 | 124 | 118 | 107 | 110 | 104 | 105 | 103 | 96.3 | 93.8 | |
Crinetics Pharmaceuticals — Stockholders' equity ($M)($M) | 1,192 | 1,281 | 992 | 1,072 | 1,172 | 1,254 | 1,325 | 833 | 831 | 875 | 539 | 548 | |
U.S. Producer Price Index (PPI) — Pharmaceutical Preparation Manufacturing (PCU325412325412, index)7 | 926.20 | 926.00 | 919.30 | 918.70 | 914.80 | 916.50 | 918.50 | 918.10 | 914.00 | 909.00 | 896.40 | 896.00 | |
U.S. PPI — Biological Product (ex-Diagnostic) Manufacturing (PCU325414325414, index) | 266.30 | 266.30 | 264.10 | 264.10 | 261.90 | 261.90 | 258.30 | 258.00 | 255.20 | 256.80 | 254.50 | 254.50 | |
U.S. PPI — Pharmaceutical & Medicine Manufacturing (PCU3254132541, index) | 245.70 | 245.80 | 244.30 | 244.00 | 242.90 | 242.80 | 242.40 | 242.30 | 241.20 | 240.30 | 237.20 | 236.90 | |
U.S. Consumer Price Index (CPI-U) — Medical Care Commodities, Seasonally Adjusted (CUSR0000SAM1, index) | 409.00 | 414.00 | 416.50 | 417.60 | 413.00 | 412.40 | 413.70 | 416.80 | 408.90 | 410.40 | 407.20 | ||
U.S. CPI-U — Medical Care Commodities, Not Seasonally Adjusted (CUUR0000SAM1, index) | 409.00 | 414.00 | 416.50 | 417.60 | 413.00 | 412.40 | 413.70 | 416.80 | 408.90 | 410.40 | 407.20 | ||
U.S. CPI-U — Medical Care, Seasonally Adjusted (CPIMEDSL, index) | 592.30 | 591.60 | 584.90 | 580.50 | 574.10 | 570.10 | 566.30 | 565.00 | 559.30 | 554.40 | 548.40 | ||
U.S. Real Personal Consumption Expenditures — Health Care Services (DHLCRC1Q027SBEA, $B SAAR) | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.90 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | 3,079.00 | |
U.S. Employment — Health Care & Social Assistance All Employees (CES6562000001, thousands) | 23,887.20 | 23,756.70 | 23,587.50 | 23,438.20 | 23,277.50 | 23,076.00 | 22,901.40 | 22,673.60 | 22,493.70 | 22,276.60 | 22,018.70 | 21,761.70 | |
Income Statement — Total revenues ($M)($M)13 | 3,334 | 2,987 | 3,190 | 3,076 | 2,965 | 2,770 | 2,912 | 2,772 | 2,646 | 2,691 | 2,518 | 2,484 | |
Cost of sales ($M)($M) | 489 | 393 | 466 | 415 | 408 | 363 | 423 | 393 | 372 | 343 | 368 | 319 | |
Research and development expenses ($M)($M) | 994 | 962 | 974 | 978 | 978 | 980 | 999 | 876 | 967 | 789 | 825 | 810 | |
Selling, general and administrative expenses ($M)($M) | 582 | 494 | 487 | 445 | 425 | 396 | 378 | 372 | 372 | 343 | 369 | 264 | |
Total costs and expenses ($M)($M) | 2,087 | 1,849 | 1,984 | 1,890 | 1,814 | 2,140 | 1,886 | 1,656 | 6,160 | 1,551 | 1,529 | 1,445 | |
Operating income (loss) ($M)($M) | 1,247 | 1,138 | 1,206 | 1,186 | 1,151 | 630 | 1,026 | 1,116 | -3,515 | 1,140 | 989 | 1,038 | |
Other non-operating income (expense), net ($M)($M) | 24.3 | 0 | 6.50 | -9.80 | 13.2 | -17.6 | -14.9 | -16.9 | -23.1 | -31.2 | -9.80 | -15.9 | |
Income (loss) before provision for income taxes ($M)($M) | 1,392 | 1,253 | 1,331 | 1,299 | 1,283 | 730 | 1,137 | 1,224 | -3,391 | 1,279 | 1,148 | 1,179 | |
Provision for (benefit from) income taxes ($M)($M) | 292 | 222 | 140 | 216 | 250 | 84.1 | 224 | 179 | 202 | 180 | 179 | 144 | |
Net income (loss) ($M)($M) | 1,100 | 1,031 | 1,191 | 1,083 | 1,033 | 646 | 913 | 1,045 | -3,594 | 1,100 | 969 | 1,035 | |
Earnings per share — Basic ($/sh)($) | 4.34 | 4.06 | 4.24 | 4.02 | 2.52 | 4.05 | -13.92 | 4.26 | 4.01 | ||||
Earnings per share — Diluted ($/sh)($) | 4.31 | 4.02 | 4.20 | 3.99 | 2.49 | 4.01 | -13.92 | 4.21 | 3.97 | ||||
Weighted-average basic shares (M)(M) | 254 | 254 | 256 | 257 | 257 | 258 | 258 | 258 | 258 | ||||
Weighted-average diluted shares (M)(M) | 255 | 256 | 258 | 259 | 260 | 261 | 258 | 261 | 261 | ||||
Balance Sheet — Total assets ($M)($M)24 | 27,423 | 26,484 | 25,643 | 24,862 | 24,037 | 22,881 | 22,533 | 22,240 | 20,132 | 23,917 | 22,730 | 21,726 | |
Cash and cash equivalents ($M)($M) | 6,144 | 5,493 | 5,085 | 4,940 | 4,972 | 4,675 | 4,570 | 5,239 | 4,580 | 9,158 | 10,369 | 11,110 | |
Marketable securities ($M)($M) | 1,709 | 1,754 | 1,523 | 1,347 | 1,411 | 1,527 | 1,546 | 1,285 | 1,215 | 1,013 | 849 | 818 | |
Accounts receivable, net ($M)($M) | 2,134 | 1,996 | 2,053 | 1,946 | 1,894 | 1,805 | 1,609 | 1,751 | 1,656 | 1,793 | 1,563 | 1,539 | |
Inventories ($M)($M) | 1,765 | 1,767 | 1,687 | 1,627 | 1,499 | 1,360 | 1,205 | 1,080 | 915 | 813 | 739 | 689 | |
Prepaid expenses and other current assets ($M)($M) | 792 | 721 | 853 | 709 | 652 | 643 | 666 | 449 | 575 | 511 | 624 | 540 | |
Total current assets ($M)($M) | 12,544 | 11,730 | 11,201 | 10,570 | 10,428 | 10,009 | 9,596 | 9,804 | 8,942 | 13,289 | 14,144 | 14,696 | |
Property and equipment, net ($M)($M) | 1,665 | 1,608 | 1,520 | 1,425 | 1,335 | 1,296 | 1,228 | 1,118 | 1,201 | 1,173 | 1,159 | 1,124 | |
Goodwill ($M)($M) | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | 1,088 | |
Intangible assets, net ($M)($M) | 413 | 419 | 424 | 430 | 436 | 441 | 826 | 832 | 838 | 835 | 840 | 604 | |
Operating lease right-of-use assets ($M)($M) | 1,663 | 1,685 | 1,563 | 1,592 | 1,314 | 1,339 | 1,357 | 1,396 | 570 | 313 | 294 | 311 | |
Deferred tax assets ($M)($M) | 3,011 | 2,948 | 2,898 | 2,937 | 2,712 | 2,544 | 2,331 | 2,309 | 2,186 | 1,963 | 1,812 | 1,729 | |
Other noncurrent assets ($M)($M) | 1,251 | 1,256 | 1,237 | 1,098 | 1,079 | 1,007 | 999 | 990 | 916 | 876 | 895 | 475 | |
Accounts payable ($M)($M) | 430 | 489 | 462 | 420 | 442 | 445 | 413 | 396 | 328 | 351 | 365 | 376 | |
Accrued expenses ($M)($M) | 3,179 | 2,984 | 2,971 | 3,614 | 3,271 | 2,952 | 2,789 | 3,220 | 2,940 | 2,796 | 2,655 | 2,907 | |
Other current liabilities ($M)($M) | 329 | 407 | 428 | 442 | 425 | 386 | 363 | 358 | 279 | 649 | 527 | 316 | |
Total current liabilities ($M)($M) | 3,938 | 3,881 | 3,861 | 4,475 | 4,138 | 3,783 | 3,565 | 3,973 | 3,547 | 3,796 | 3,547 | 3,599 | |
Noncurrent operating lease liabilities ($M)($M) | 1,978 | 1,987 | 1,847 | 1,835 | 1,527 | 1,538 | 1,544 | 1,589 | 587 | 360 | 349 | 354 | |
Other long-term liabilities ($M)($M) | 1,260 | 1,255 | 1,270 | 1,233 | 1,196 | 952 | 1,015 | 933 | 877 | 854 | 878 | 869 | |
Total liabilities ($M)($M) | 7,175 | 7,123 | 6,977 | 7,544 | 6,861 | 6,384 | 6,124 | 6,609 | 5,357 | 5,371 | 5,150 | 5,213 | |
Additional paid-in capital ($M)($M) | 4,506 | 4,743 | 5,119 | 5,012 | 5,988 | 6,173 | 6,672 | 6,906 | 7,101 | 7,285 | 7,450 | 7,340 | |
Retained earnings (accumulated deficit) ($M)($M) | 15,691 | 14,591 | 13,560 | 12,369 | 11,286 | 10,253 | 9,607 | 8,694 | 7,648 | 11,242 | 10,142 | 9,174 | |
Accumulated other comprehensive income (loss) ($M)($M) | 48.5 | 24.8 | -15.9 | -64.5 | -101 | 68.1 | 128 | 28.8 | 22.5 | 17.3 | -14.3 | -3 | |
Total stockholders' equity ($M)($M) | 20,248 | 19,362 | 18,666 | 17,319 | 17,175 | 16,496 | 16,410 | 15,631 | 14,775 | 18,547 | 17,580 | 16,513 | |
Common shares outstanding at period-end (M)(M) | 253 | 254 | 254 | 254 | 256 | 257 | 257 | 258 | 258 | 258 | 258 | 258 | |
Cash Flow — Operating cash flow ($M)($M)10 | 1,125 | 1,428 | 498 | 1,241 | 1,073 | 819 | 585 | 1,370 | -3,754 | 1,307 | 235 | 1,268 | |
Depreciation and amortization ($M)($M) | 56.5 | 55.9 | 55.7 | 54 | 51.7 | 48.4 | 46.5 | 53.2 | 54 | 53.5 | 59 | 42.1 | |
Stock-based compensation ($M)($M) | 170 | 166 | 158 | 195 | 167 | 166 | 168 | 185 | 154 | 192 | 209 | 131 | |
Change in accounts receivable ($M)($M) | -140 | 39.8 | -99.4 | -59.9 | -18.4 | -170 | 69 | -51.8 | 135 | -252 | 15.4 | -6.10 | |
Change in inventories ($M)($M) | -27.7 | -97.7 | -77.4 | -131 | -149 | -167 | -148 | -183 | -107 | -80.1 | -70 | -97.5 | |
Change in accounts payable and accrued expenses ($M)($M) | -66.7 | 35.6 | 38.3 | -35.3 | 7.60 | 26.2 | 8.40 | 66.1 | -25.1 | 0.10 | -31.8 | 9.20 | |
Capital expenditures ($M)($M) | 112 | 133 | 149 | 102 | 146 | 40.7 | 92.6 | 67.7 | 69 | 68.4 | 58.1 | 40.6 | |
Net cash used in investing activities ($M)($M) | -45.8 | -432 | -288 | -117 | -485 | -55.8 | -822 | -348 | -464 | -2,136 | -887 | -118 | |
Repurchases of common stock ($M)($M) | 470 | 337 | 128 | 1,071 | 392 | 426 | 418 | 308 | 320 | 131 | 150 | 117 | |
Net cash used in financing activities ($M)($M) | -427 | -539 | -77.2 | -1,155 | -349 | -680 | -391 | -388 | -359 | -358 | -120 | -165 | |
Cash paid for income taxes ($M)($M) | 419 | 82.3 | 389 | 480 | 513 | 184 | 272 | 279 | 497 | 34.8 | 758 | 300 | |
13 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Vertex Pharmaceuticals Incorporated operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Vertex operates as a single global human therapeutics operating segment (pharmaceuticals), disaggregating commercial performance across its Cystic Fibrosis (CF) portfolio (TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO), Diversified Launch portfolio (CASGEVY gene-edited therapy and JOURNAVX non-opioid pain inhibitor), and Geographic markets (U.S. vs. Ex-U.S. [Europe & Other International]).
- Core operational & commercial KPIs (Groups 1–5) cover: (1) Commercial Launch, Patient Access & Wholesaler Concentration (Core CF addressable population of 97,000 patients in FY25; JOURNAVX prescriptions filled reaching 535,000 in Q2 2026 after 350,000 in Q1 2026 and 550,000 in FY25, with 21 state Medicaid plans at FY25; CASGEVY patient infusions of 64 in FY25 [30 in Q4 2025] and 147 first cell collections in FY25; Customer Concentration across McKesson 32% of gross revenue, Accredo 26%, and Lloyds Pharmacy 15% in FY25); (2) Net Product & Collaborative Revenues by Brand & Geography ($3,381.9M in Q2 2026 / $12,003.0M in FY25 across TRIKAFTA/KAFTRIO $2,505.5M, ALYFTREK $430.5M, CASGEVY $67.7M, JOURNAVX $66.3M, Other CF $277.6M in Q2 2026; U.S. $2,115.6M vs. Ex-U.S. $1,232.0M in Q2 2026); (3) Gross-to-Net (GTN) Rebate Accruals Rollforward ($4,043.6M current-year provision and $1,984.9M ending balance at FY25), Ex-U.S. CF Annual Reimbursement Cap Contract Liabilities ($265.2M at Q2 2026), Accrued Expenses breakdown, and Level 3 Contingent Consideration; (4) Granular R&D Disaggregation (Research $235.1M vs. Development $795.4M in Q2 2026 broken down into Salary & Benefits, SBC, Outsourced CRO/Clinical Services, and Infrastructure), Segment Expenses (Product COGS vs. Royalty COGS, Selling vs. G&A), and CRISPR Therapeutics CASGEVY JDCA (60%/40% profit/cost split); and (5) Form 8-K GAAP to Non-GAAP Reconciliations ($1,301.2M Non-GAAP Net Income and $5.03 Non-GAAP Diluted EPS in Q2 2026).
- Extended operational, subsidiary & ESG KPIs (Groups 6–11) cover: (6) Stock-Based Compensation by line item and award type (RSU/PSU, Stock Options, ESPP) plus full share & fair value rollforwards; (7) Inventories by stage ($1,341.0M net at Q2 2026 across Raw Materials $334.4M, WIP $798.5M, Finished Goods $208.1M), PP&E by asset class, Geographic Long-Lived Assets (U.S., U.K., Other), Intangibles/IPR&D, and Operating & Finance Leases; (8) Monthly & Quarterly Share Repurchases from Item 2(c)/Item 5 (76 months through June 2026), Domestic vs. Foreign Pre-Tax Income, DTA/DTL breakdown, NOL/Tax Credit carryforwards, and Unrecognized Tax Benefits (UTB) rollforward; (9) Workforce by region (~6,600 total employees in FY25: 4,600 U.S. and 2,000 Ex-U.S.), DEF 14A CEO & NEO Pay Versus Performance and CEO Pay Ratio (80:1 in FY25; median employee $242,400), and Corporate Responsibility / ESG metrics (Scope 1, 2 & 3 GHG emissions, 73% renewable electricity, 82% green buildings, waste diversion, water, TRIR 0.13); (10) Audited UK Companies House statutory accounts (OCR) for Vertex Pharmaceuticals (Europe) Limited (02907620: $12,783.7M turnover, $999.9M net profit, $4,763.9M net assets in FY25) plus SEC XBRL for acquired subsidiaries Alpine Immune Sciences and Crinetics Pharmaceuticals; and (11) FRED Healthcare/Pharma Benchmarks and PostgreSQL DB Financial Statements.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I as restricted net assets of subsidiaries are below the 25% threshold), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted and OCR metrics; bound disclosures such as Q4 2025 JOURNAVX 'over 200 million covered lives' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (11)
- Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx) › JOURNAVX — Covered lives across commercial & government payers (millions)
- Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx) › JOURNAVX — Covered lives with unrestricted access (no prior auth / step edit) (millions)
- Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › CASGEVY (exagamglogene autotemcel, CRISPR/Cas9 gene-edited therapy) — Patient infusions in period (patients) › CASGEVY — Cumulative patients infused since launch (patients)
- Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) — Countries with regulatory approval / reimbursement access (countries)
- Net Product & Collaborative Revenues by Brand / Therapy & Geography › Total consolidated revenues ($M) › Net product revenues — Total ($M) › Cystic Fibrosis (CF) portfolio — Total CF net product revenues ($M)
- Net Product & Collaborative Revenues by Brand / Therapy & Geography › Total consolidated revenues ($M) › Net product revenues — Total ($M) › Other CF products (SYMDEKO/SYMKEVI, ORKAMBI & KALYDECO combined, FY2024, $M)
- Net Product & Collaborative Revenues by Brand / Therapy & Geography › Total consolidated revenues ($M) › Other revenues (collaborative & royalty revenues, $M) › Collaborative revenues (standalone historical, $M)
- Granular R&D Breakdown (Research vs. Development), Segment Expenses & CRISPR Collaboration › Total Research and Development (R&D) expenses ($M) › Development expenses (clinical trials, regulatory & CMC) — Total ($M) › Development — Collaborative & milestone payments (FY2017–FY2021, $M)
- Granular R&D Breakdown (Research vs. Development), Segment Expenses & CRISPR Collaboration › CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) › CRISPR Collaboration — AIPR&D upfront & milestone expense ($M)
- Share Repurchases (Monthly & Quarterly) & Income Taxes / UTB Rollforward › Net deferred tax assets (after valuation allowance & deferred tax liabilities, $M) › Net operating loss (NOL) carryforwards — U.S. federal ($M) › Tax credit carryforwards — U.S. federal ($M)
- Subsidiary Statutory Filings (UK Companies House OCR) & Acquired Biotech Subsidiaries (Alpine & Crinetics) › Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) › Crinetics Pharmaceuticals — Selling, general and administrative expense ($M)
Dữ liệu cập nhật 2026-11-02.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration
- Estimated Cystic Fibrosis (CF) patient population in U.S., Europe, Australia & Canada (patients)11 kỳ
- JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx)6 kỳ
- CASGEVY (exagamglogene autotemcel, CRISPR/Cas9 gene-edited therapy) — Patient infusions in period (patients)4 kỳ
- Customer Concentration — McKesson Corp. share of gross product revenues (%) (%)10 kỳ
Net Product & Collaborative Revenues by Brand / Therapy & Geography
Gross-to-Net (GTN) Rebate Rollforward, Ex-U.S. Cap Contracts, Accrued Expenses & Contingent Consideration
Granular R&D Breakdown (Research vs. Development), Segment Expenses & CRISPR Collaboration
- Total Research and Development (R&D) expenses ($M) ($M)70 kỳ
- Acquired in-process research and development (AIPR&D) expenses ($M) ($M)17 kỳ
- Cost of sales — Total ($M) ($M)63 kỳ
- Selling, general and administrative (SG&A) expenses — Total ($M) ($M)70 kỳ
- CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) ($M)24 kỳ
Non-GAAP Financial Performance & Reconciliations (Form 8-K Earnings Releases)
Stock-Based Compensation (by Line Item & Award Type) & Equity Plan Rollforwards
- Total stock-based compensation (SBC) expense recognized in income statement ($M) ($M)46 kỳ
- SBC expense by award type — Restricted stock units (RSUs) & performance stock units (PSUs) ($M) ($M)32 kỳ
- Restricted Stock Units (RSUs) — Nonvested shares outstanding at period-end (M shares) (M)11 kỳ
- Performance Stock Units (PSUs) — Nonvested shares outstanding at period-end (M shares) (M)10 kỳ
- Stock Options — Shares outstanding at period-end (M shares) (M)11 kỳ
Inventories by Stage, PP&E by Asset Class, Geographic Long-Lived Assets, Intangibles & Leases
Share Repurchases (Monthly & Quarterly) & Income Taxes / UTB Rollforward
- Share repurchases — Cash paid for repurchases of common stock ($M) ($M)38 kỳ
- Income before provision for income taxes — Total ($M) ($M)65 kỳ
- Provision for (benefit from) income taxes — Total ($M) ($M)62 kỳ
- Net deferred tax assets (after valuation allowance & deferred tax liabilities, $M) ($M)9 kỳ
- Unrecognized tax benefits (UTB) — Gross ending balance ($M) ($M)11 kỳ
Workforce by Region, Executive Compensation (DEF 14A) & Corporate Responsibility / ESG
- Global workforce — Total employees (headcount)12 kỳ
- Executive Compensation (DEF 14A) — CEO Summary Compensation Table (SCT) total ($M) ($M)6 kỳ
- Environment & Climate — Total Scope 1 & Scope 2 (market-based) GHG emissions (metric tons CO2e)7 kỳ
- Waste & Water — Total operational waste generated (metric tons)6 kỳ
- Workplace Safety, Governance & Community — Total Recordable Incident Rate (TRIR per 200,000 hours)7 kỳ
- Workforce & Board Representation (FY2019–FY2023) — Women in global workforce (%) (%)5 kỳ
Subsidiary Statutory Filings (UK Companies House OCR) & Acquired Biotech Subsidiaries (Alpine & Crinetics)
- Vertex Pharmaceuticals (Europe) Limited (UK 02907620, Ex-North America IP & Commercial Hub) — Turnover / Revenue ($M) ($M)8 kỳ
- Vertex Pharmaceuticals (Europe) Limited (UK 02907620) — Net assets / Total equity ($M) ($M)8 kỳ
- Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M) ($M)25 kỳ
- Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) ($M)34 kỳ
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Vertex Pharmaceuticals
- Form 10-Q (filed 2026-08-04) ↗
- Form 10-K (filed 2026-02-13) ↗
- Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
- Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
- Vertex Corporate Responsibility / ESG Report (2025-Vertex-Data-Summary.pdf) ↗
- FRED (PCU325412325412) ↗
- Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
- Vertex Pharmaceuticals (Europe) Limited (02907620) ↗
- Earnings Call Transcript () ↗
- Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗
- Vertex Corporate Responsibility / ESG Report (NASDAQ_VRTX_2023.pdf) ↗
- SEC Filing ↗
See a number that looks wrong?